Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC
833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be
killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective
than combination chemotherapy alone in treating patients with relapsed or refractory multiple
myeloma.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B European Organisation for Research and Treatment of Cancer - EORTC National Cancer Institute (NCI) NCIC Clinical Trials Group Southwest Oncology Group